Year in Review: Multiple Myeloma

(MedPage Today) -- Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news